Literature DB >> 7904161

Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease.

S Ishii1, R Kase, H Sakuraba, Y Suzuki.   

Abstract

The expression product of a mutant alpha-galactosidase gene, Q279E (279Gln-->Glu), found in an atypical variant (cardiac form) of Fabry disease, was purified and characterized. It had kinetic properties similar to those of normal alpha-galactosidase, but was markedly thermolabile at neutral pH. Galactose and melibiose at high concentrations stabilized the mutant enzyme in vitro. Its catalytic activity was 15% of that for the normal enzyme, when it was expressed in COS-1 cells at 37 degrees C. The activity increased at 30 degrees C or in the presence of galactose at 37 degrees C. An increase was also observed in lymphoblasts from a patient with this mutation in the presence of galactose or melibiose. We conclude that this mutant protein is posttranslationally inactivated under the neutral conditions in the cells. The possibility of a new therapeutic approach is suggested.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904161     DOI: 10.1006/bbrc.1993.2659

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

Review 2.  Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

Authors:  Susan L Lindquist; Jeffery W Kelly
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

3.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

4.  Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys.

Authors:  Takahiro Tsukimura; Ikuo Kawashima; Tadayasu Togawa; Takashi Kodama; Toshihiro Suzuki; Toru Watanabe; Yasunori Chiba; Yoshifumi Jigami; Tomoko Fukushige; Takuro Kanekura; Hitoshi Sakuraba
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 5.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

6.  Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins.

Authors:  T Okumiya; S Ishii; R Kase; S Kamei; H Sakuraba; Y Suzuki
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

7.  Fabry disease - current treatment and new drug development.

Authors:  Omid Motabar; Ellen Sidransky; Ehud Goldin; Wei Zheng
Journal:  Curr Chem Genomics       Date:  2010-07-23

8.  Alpha-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues.

Authors:  S Ishii; R Kase; H Sakuraba; C Taya; H Yonekawa; T Okumiya; Y Matsuda; K Mannen; M Takeshita; Y Suzuki
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

9.  A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier.

Authors:  M Uchino; E Uyama; H Kawano; J Hokamaki; K Kugiyama; Y Murakami; H Yasue; M Ando
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities.

Authors:  Yoshiyuki Suzuki; Seiichiro Ogawa; Yasubumi Sakakibara
Journal:  Perspect Medicin Chem       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.